Germany-based global drugmaker Bayer and Rockland, Mass.-based EMD Serono will limit drug discounts ensured through the 340B program to covered entities and not include contract pharmacies. The changes are effective March 1, Bayer and EMD Serono said in letters
340B Health said these are the 20th and 21st drugmakers to narrow discounted drugs to 340B hospitals, which care for an uninsured community. The others are AbbVie, Amgen, AstraZeneca, Bausch Health, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Exelixis, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, UCB and United Therapeutics, the organization said.
The news comes two days after an appeals court ruled that Sanofi, AstraZeneca and Novo Nordisk can deny the drug discounts to contract pharmacies.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
